We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Mapping Catheter Helps Identify Ablation Hotspots

By HospiMedica International staff writers
Posted on 10 Apr 2018
A unique nerve mapping technology provides more effective renal denervation (RDN) treatment for resistant hypertension.

The Pythagoras Medical (Hertzliya, Israel) ConfidenHT system is based on a multi-electrode, non-occluding flexible over-the-wire catheter with an expendable multi electrode design compatible with an 8 French guiding catheter and 0.014" guide wire, suitable for a wide range of renal artery diameters. More...
The electrical stimulation of sympathetic fibers in the renal arteries elicits a reciprocal sympathetic response, which in turn induces a transient change in several physiological measurable parameters, such as heart rate and blood pressure, and allows real time intra-arterial blood pressure monitoring.

The mapping catheter features multi-channel stimulation capabilities and an algorithm that uses the multi-factorial physiological responses to create a map of hotspots for ablation. Stimulation outcomes are displayed on the proprietary 15" touch screen ConfidenHT mapping console, which also provides visualization of the artery's mapping results and hot-spot locations. The technology also reduces the risk factor associated with unnecessary ablation, as it also verifies ablation effectiveness and identifies non-responder patients.

“This renal fiber stimulation project is, without a doubt, a very promising step in our endeavor to locate the ‘sweet-spots’ where renal ablation produces will achieve the best results,” said Professor Konstantinos Tsioufis, MD, PhD, of Hippocratio Hospital (Athens, Greece), president of the European Society of Hypertension (ESH). “Our preliminary experience seems to bring us closer to the goal of ‘unblinding’ the renal denervation procedure.”

RDN is a minimally invasive, radiofrequency (RF) or ultrasound ablation procedure aimed at treating resistant hypertension. Nerves in the wall of the renal artery are ablated, which causes reduction of sympathetic afferent and efferent activity to the kidney, decreasing blood pressure. While early data from international clinical trials demonstrated large blood pressure reductions in patients with treatment-resistant hypertension, a 2014 a prospective, sham-controlled clinical trial failed to confirm this finding.

Related Links:
Pythagoras Medical
Hippocratio Hospital


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Electric Bed
DIXION Intensive Care Bed
New
High-Precision QA Tool
DEXA Phantom
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.